Various pharmacologic agents have been used for perioperative BP control in pediatric patients, including sodium nitroprusside, nitroglycerin, β-adrenergic antagonists, fenoldopam, and calcium channel antagonists. Of the calcium antagonists, the majority of the clinical experience remains with the dihydropyridine nicardipine. Clevidipine is a short-acting, intravenous calcium channel antagonist of the dihydropyridine class. It undergoes rapid metabolism by non-specific blood and tissue esterases with a half-life of less than 1 minute. As a dihydropyridine, its cellular and end-organ effects parallel those of nicardipine. The clevidipine trials in the adult population have demonstrated efficacy in rapidly controlling BP in various clinical scenarios with a favorable adverse effect profile similar to nicardipine. Data from large clinical trials regarding the safety and efficacy of clevidipine in children is lacking. This manuscript aims to review the commonly used pharmacologic agents for perioperative BP control in children, discuss the role of calcium channel antagonists such as nicardipine, and outline the preliminary data regarding clevidipine in the pediatric population.
References
[1]
Seltzer, J.L. Etiology and prevention of perioperative hypertension. Surg. Rounds 1987, 10, 711–724.
[2]
Flynn, J.T. Hypertension in the young: Epidemiology, sequelae and therapy. Nephrol. Dial. Transpl. 2009, 24, 370–375, doi:10.1093/ndt/gfn597.
[3]
Flynn, J.T.; Tullus, K. Severe hypertension in children and adolescents: Pathophysiology and treatment. Pediatr. Nephrol. 2009, 24, 1101–1112, doi:10.1007/s00467-008-1000-1.
[4]
Marik, P.E.; Varon, J. Perioperative hypertension: A review of current and emerging therapeutic agents. J. Clin. Anesth. 2009, 21, 220–229, doi:10.1016/j.jclinane.2008.09.003.
[5]
Desai, R.G.; Muntazar, M.; Goldberg, M.E. Strategies for managing perioperative hypertension. Curr. Hypertens. Rep. 2009, 11, 173–177, doi:10.1007/s11906-009-0031-8.
[6]
Gordillo-Paniagua, G.; Velasquez-Jones, L.; Martini, R.; Valdez-Bolanos, E. Sodium nitroprusside treatment of severe arterial hypertension in children. J. Pediatr. 1975, 87, 799–802, doi:10.1016/S0022-3476(75)80314-3.
[7]
Khambatta, H.J.; Stone, J.G.; Khan, E. Hypertension during anesthesia on discontinuation of sodium nitroprusside-induced hypotension. Anesthesiology 1979, 51, 127–130, doi:10.1097/00000542-197908000-00007.
[8]
Rowe, G.G.; Henderson, R.H. Systemic and coronary hemodynamic effects of sodium nitroprusside. Am. Heart J. 1974, 87, 83–87.
[9]
Sivarajan, M.; Amory, D.W.; McKenzie, S.M. Regional blood flows during induced hypotension produced by nitroprusside or trimethaphan in the rhesus monkey. Anesth. Analg. 1985, 64, 759–766.
[10]
Michenfelder, J.D.; Milde, J.H. The interaction of sodium nitroprusside, hypotension, and isoflurane in determining cerebral vasculature effects. Anesthesiology 1988, 69, 870–875, doi:10.1097/00000542-198812000-00011.
[11]
Hines, R.; Barash, P.G. Infusion of sodium nitroprusside induces platelet dysfunction in vitro. Anesthesiology 1989, 70, 611–615, doi:10.1097/00000542-198904000-00010.
[12]
Davies, D.W.; Greiss, L.; Kadar, D.; Steward, D.J. Sodium nitroprusside in children: Observations on metabolism during normal and abnormal responses. Can. J. Anesth. 1975, 22, 553–560, doi:10.1007/BF03013408.
[13]
Rawlinson, W.A.; Loach, A.B.; Benedict, C.R. Changes in plasma concentration of adrenaline and noradrenaline in anaesthetized patients during sodium nitroprusside-induced hypotension. Br. J. Anaesth. 1978, 50, 937–943, doi:10.1093/bja/50.9.937.
Moffett, B.S.; Price, J.F. Evaluation of sodium nitroprusside toxicity in pediatric cardiac surgical patients. Ann. Pharmacother. 2008, 42, 1600–1604, doi:10.1345/aph.1L192.
[16]
Fahmy, N.R. Nitroglycerin as a hypotensive drug during general anesthesia. Anesthesiology 1978, 49, 17–20, doi:10.1097/00000542-197807000-00006.
[17]
Yaster, M.; Simmons, R.S.; Tolo, V.T.; Pepple, J.M.; Wetzel, R.C.; Rogers, M.C. A comparison of nitroglycerin and nitroprusside for inducing hypotension in children: A double-blind study. Anesthesiology 1986, 65, 175–179, doi:10.1097/00000542-198608000-00008.
Lagerkranser, M. Effects of nitroglycerin on intracranial pressure and cerebral blood flow. Acta. Anaesth. Scand. 1992, 36, 34–36, doi:10.1111/j.1399-6576.1992.tb03585.x.
[20]
Edmondson, R.; del Valle, O.; Shah, N.; Wong, G.; Dwyer, D.; Matarazzo, D.; Thorne, A.; Coffey, C.; Bedford, R. Esmolol for potentiation of nitroprusside-induced hypotension impact on the cardiovascular, adrenergic, and renin-angiotensin systems in man. Anesth. Analg. 1989, 69, 202–206.
[21]
Orlowski, J.P.; Shiesley, D.; Vidt, D.G.; Barnett, G.H.; Little, J.R. Labetalol to control blood pressure after cerebrovascular surgery. Crit. Care Med. 1988, 16, 765–768, doi:10.1097/00003246-198808000-00006.
[22]
Rose, J.C.; Mayer, S.A. Optimizing blood pressure in neurological emergencies. Neurocrit. Care 2004, 1, 287–299, doi:10.1385/NCC:1:3:287.
[23]
De Hert, S.; Boeckx, E.; Vercauteren, M.; Claes, J.; van den Heyning, P.; Adriaensen, H. Safety of labetalol-induced controlled hypotension during middle ear microsurgery. Acta. Otorhinolaryngol. Belg.. 1989, 43, 157–162.
[24]
Casthely, P.A.; Villanueva, R.; Rabinowitz, L.; Gandhi, P.; Litwak, B.; Fyman, P.N. Intrapulmonary shunting during deliberate hypotension with nifedipine, diltiazem and labetalol in dogs. Can. J. Anesth. 1985, 32, 119–123, doi:10.1007/BF03010034.
[25]
Bunchman, T.E.; Lynch, R.E.; Wood, E.G. Intravenously administered labetalol for treatment of hypertension in children. J. Pediatr. 1992, 120, 140–144, doi:10.1016/S0022-3476(05)80619-5.
[26]
Thomas, C.A.; Moffett, B.S.; Wagner, J.L.; Mott, A.R.; Feig, D.I. Safety and efficacy of intravenous labetalol for hypertensive crisis in infants and small children. Pediatr. Crit. Care Me. 2011, 12, 28–32, doi:10.1097/PCC.0b013e3181e328d8.
[27]
Tabbutt, S.; Nicolson, S.C.; Adamson, P.C.; Zhang, X.; Hoffman, M.L.; Wells, W.; Backer, C.L.; McGowan, F.X.; Tweddell, J.S.; Bokesch, P. The safety, efficacy, and pharmacokinetics of esmolol for blood pressure control immediately after repair of coarctation of the aorta in infants and children: A multicenter, double-blind, randomized trail. J. Thorac. Cardiov. Sur. 2008, 136, 321–328, doi:10.1016/j.jtcvs.2007.09.086.
[28]
Wiest, D.B.; Garner, S.S.; Uber, W.E.; Sade, R.M. Esmolol for the management of pediatric hypertension after cardiac operations. J. Thorac. Cardiov. Sur 1998, 115, 890–897, doi:10.1016/S0022-5223(98)70371-X.
[29]
Tobias, J.D.; Sauder, R.A.; Hirshman, C.A. Pulmonary reactivity to methacholine during beta-adrenergic blockade: Propranolol versus esmolol. Anesthesiology 1990, 73, 132–136.
[30]
Strauser, L.M.; Pruitt, R.D.; Tobias, J.D. Initial experience with fenoldopam in children. Am. J. Ther. 1999, 6, 283–288, doi:10.1097/00045391-199909000-00007.
[31]
Tobias, J.D. Fenoldopam for controlled hypotension during spinal fusion in children and adolescents. Pediatr. Anesth. 2000, 10, 261–266, doi:10.1046/j.1460-9592.2000.00502.x.
[32]
Hammer, G.B.; Verghese, S.T.; Drover, D.R.; Yaster, M.; Tobin, J.R. Pharmacokinetics and pharmacodynamics of fenoldopam mesylate for blood pressure control in pediatric patients. BMC Anesthesiol. 2008, 8, 6, doi:10.1186/1471-2253-8-6.
[33]
Devlin, J.W.; Seta, M.L.; Kanji, S.; Somerville, A.L. Fenoldopam versus nitroprusside for the treatment of hypertensive emergency. Ann. Pharmacother. 2004, 38, 755–759, doi:10.1345/aph.1D363.
[34]
Moffett, B.S.; Mott, A.R.; Nelson, D.P.; Goldstein, S.L.; Jefferies, J.L. Renal effects of fenoldopam in critically ill pediatric patients: A retrospective review. Pediatr. Crit. Care Me. 2008, 9, 403–406, doi:10.1097/PCC.0b013e3181728c25.
[35]
Tobias, J.D. Nicardipine: Applications in anesthesia practice. J. Clin. Anesth. 1995, 7, 525–533, doi:10.1016/0952-8180(95)00093-W.
[36]
Clark, B.; Eglen, R.M.; Patmore, L.; Whiting, R.L. Cardioselective calcium channel entry blocking properties of nicardipine, nifedipine, and py-108068 on cardiac and vascular smooth muscle. Br. J. Pharmacol. 1983, 79, 333P–337P.
[37]
Lambert, C.R.; Hill, J.A.; Nichols, W.W.; Feldman, R.L.; Pepine, C.J. Coronary and systemic hemodynamic effects of nicardipine. Am. J. Cardiol. 1985, 55, 652–656, doi:10.1016/0002-9149(85)90130-4.
[38]
Rousseau, M.F.; Etienne, J.; van Mechelen, H.; Veriter, C.; Pouleur, H. Hemodynamic and cardiac effects of nicardipine in patients with coronary artery disease. J. Cardiovasc. Pharm. 1984, 6, 833–839, doi:10.1097/00005344-198409000-00015.
[39]
Tobias, J.D. Nicardipine to control mean arterial pressure after cardiothoracic surgery in infants and children. Am. J. Ther. 2001, 8, 3–6, doi:10.1097/00045391-200101000-00002.
Hersey, S.L.; O'Dell, N.E.; Lowe, S.; Rasmussen, G.; Tobias, J.D.; Deshpande, J.K.; Mencio, G.; Green, N. Nicardipine versus nitroprusside for controlled hypotension during spinal surgery in adolescents. Anesth. Analg. 1997, 84, 1239–1244.
[42]
Nakagawa, T.A.; Sartori, S.C.; Morris, A.; Schneider, D.S. Intravenous nicardipine for treatment of postcoarctectomy hypertension in children. Pediatr. Cardiol. 2004, 25, 26–30, doi:10.1007/s00246-003-0497-0.
[43]
Flynn, J.T.; Mottes, T.A.; Brophy, P.D.; Kershaw, D.B.; Smoyer, W.E.; Bunchman, T.E. Intravenous nicardipine for treatment of severe hypertension in children. J. Pediatr. 2001, 139, 38–43, doi:10.1067/mpd.2001.114030.
[44]
Bernard, J.M.; Pinaud, M.; Francois, T.; Babin, M.; Macquin-Mavier, I.; Letenneur, J. Deliberate hypotension with nicardipine or nitroprusside during total hip arthroplasty. Anesth. Analg. 1991, 73, 341–345.
[45]
Bernard, J.M.; Passuti, N.; Pinaud, M. Long term hypotensive technique with nicardipine and nitroprusside during isoflurane anesthesia for spinal surgery. Anesth. Analg 1992, 75, 179–185.
[46]
Nordlander, M.; Sjoquist, P.O.; Ericsson, H.; Ryden, L. Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control. Cardiovasc. Drug Rev. 2004, 22, 227–250.
[47]
Schulz, L.T.; Elder, J.E.J.; Jones, K.J.; Vijayan, A.; Johnson, B.D.; Medow, J.E.; Vermeulen, L. Stability of sodium nitroprusside and sodium thiosulfate 1:10 intravenous admixture. Hosp. Pharm. 2010, 45, 779–784, doi:10.1310/hpj4510-779.
[48]
Levy, J.H.; Mancao, M.Y.; Gitter, R.; Kereiakes, D.J.; Grigore, A.M.; Aronson, S.; Newman, M.F. Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: The results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1. Anesth. Analg. 2007, 105, 918–925.
[49]
Singla, N.; Warltier, D.C.; Gandhi, S.D.; Lumb, P.D.; Sladen, R.N.; Aronson, S.; Newman, M.F.; Corwin, H.L. Treatment of acute postoperative hypertension in cardiac surgery patients: An efficacy study of clevidipine assessing its postoperative antihypertensive effect in cardiac surgery-2 (escape-2), a randomized, double-blind, placebo-controlled trial. Anesth. Analg. 2008, 107, 59–67.
[50]
Aronson, S.; Dyke, C.M.; Stierer, K.A.; Levy, J.H.; Cheung, A.T.; Lumb, P.D.; Kereiakes, D.J.; Newman, M.F. The eclipse trials: Comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients. Anesth. Analg. 2008, 107, 1110–1121.
[51]
Tobias, J.D.; Allee, J.; Ramachandran, V.; Groshong, T. Clevidipine controls intraoperative blood pressure in an adolescent with renal failure. J. Pediatr. Pharmacol. Ther. 2009, 14, 144–147.
[52]
Towe, E.; Tobias, J.D. Preliminary experience with clevidipine in the pediatric population. J. Intensive Care Med. 2010, 25, 349–352, doi:10.1177/0885066610377977.
[53]
Bettesworth, J.G.; Martin, D.P.; Tobias, J.D. Intraoperative use of clevidipine in a patient with von hippel-lindau disease with associated pheochromocytoma. J. Cardiothor. Vasc. An. 2012.
[54]
Tobias, J.D.; Schechter, W.S.; Phillips, A.; Weinstein, S.; Michler, R.; Berkenbosch, J.W.; Montoya, C. Clevidipine for perioperative blood pressure control in infants and children undergoing cardiac surgery for congenital heart disease. J. Pediatr. Pharmacol. Ther. 2011, 16, 55–60.
[55]
Tobias, J.D.; Hoernschemeyer, D.G. Clevidipine for controlled hypotension during spinal surgery in adolescents. J. Neurosurg. Anesth. 2011, 23, 347–351, doi:10.1097/ANA.0b013e31821f92b7.
[56]
Smith, W.B.; Marbury, T.C.; Komjathy, S.F.; Sumeray, M.S.; Williams, G.C.; Hu, M.; Mould, D.R. Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension. Eur. J. Clin. Pharmacol. 2012, 1–10.
[57]
Milou, C.; Debuche-Benouachkou, V.; Semama, D.S.; Germain, J.G.; Gouyon, J.B. Intravenous nicardipine as a first-line antihypertensive drug in neonates. Intensive Care Med. 2000, 26, 956–958, doi:10.1007/s001340051287.
